» Articles » PMID: 27995549

Consensus Guidelines for Diagnosis, Treatment and Follow-up of Patients with Pancreatic Cancer in Spain

Abstract

The management of patients with pancreatic cancer has advanced over the last few years. We convey a multidisciplinary group of experts in an attempt to stablish practical guidelines for the diagnoses, staging and management of these patients. This paper summarizes the main conclusions of the working group. Patients with suspected pancreatic ductal adenocarcinoma should be rapidly evaluated and referred to high-volume centers. Multidisciplinary supervision is critical for proper diagnoses, staging and to frame a treatment plan. Surgical resection together with chemotherapy offers the highest chance for cure in early stage disease. Patients with advanced disease should be classified in treatment groups to guide systemic treatment. New chemotherapeutic regimens have resulted in improved survival. Symptomatic management is critical in this disease. Enrollment in a clinical trial is, in general, recommended.

Citing Articles

Comparison of Multiple Radiomics Models for Identifying Histological Grade of Pancreatic Ductal Adenocarcinoma Preoperatively Based on Multiphasic Contrast-Enhanced Computed Tomography: A Two-Center Study in Southwest China.

Liao H, Li Y, Yang Y, Liu H, Zhang J, Liang H Diagnostics (Basel). 2022; 12(8).

PMID: 36010267 PMC: 9406915. DOI: 10.3390/diagnostics12081915.


Immunotherapy as a Therapeutic Strategy for Gastrointestinal Cancer-Current Treatment Options and Future Perspectives.

Koustas E, Trifylli E, Sarantis P, Papadopoulos N, Karapedi E, Aloizos G Int J Mol Sci. 2022; 23(12).

PMID: 35743107 PMC: 9224428. DOI: 10.3390/ijms23126664.


Importance of mutation for the current treatment of pancreatic cancer beyond maintenance.

Martinez-Galan J, Rodriguez I, Caba O World J Gastroenterol. 2021; 27(39):6515-6521.

PMID: 34754149 PMC: 8554401. DOI: 10.3748/wjg.v27.i39.6515.


Systematic appraisal of guidelines for the diagnosis of pancreatic cancer.

Liu X, Yang T, Shi X, Xiao B, An L, Zheng S Gland Surg. 2021; 10(4):1487-1498.

PMID: 33968700 PMC: 8102215. DOI: 10.21037/gs-20-676.


Tumor-Stromal Interactions in a Co-Culture Model of Human Pancreatic Adenocarcinoma Cells and Fibroblasts and Their Connection with Tumor Spread.

Prieto-Garcia E, Diaz-Garcia C, Agudo-Lopez A, Pardo-Marques V, Garcia-Consuegra I, Asensio-Pena S Biomedicines. 2021; 9(4).

PMID: 33807441 PMC: 8065458. DOI: 10.3390/biomedicines9040364.


References
1.
Andriulli A, Festa V, Botteri E, Valvano M, Koch M, Bassi C . Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies. Ann Surg Oncol. 2011; 19(5):1644-62. DOI: 10.1245/s10434-011-2110-8. View

2.
Morris-Stiff G, Taylor M . Ca19-9 and pancreatic cancer: Is it really that good?. J Gastrointest Oncol. 2012; 3(2):88-9. PMC: 3397655. DOI: 10.3978/j.issn.2078-6891.2012.016. View

3.
Von Hoff D, Ervin T, Arena F, Chiorean E, Infante J, Moore M . Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369(18):1691-703. PMC: 4631139. DOI: 10.1056/NEJMoa1304369. View

4.
Varadhachary G, Tamm E, Abbruzzese J, Xiong H, Crane C, Wang H . Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006; 13(8):1035-46. DOI: 10.1245/ASO.2006.08.011. View

5.
Nishida K, Kaneko T, Yoneda M, Nakagawa S, Ishikawa T, Yamane E . Doubling time of serum CA 19-9 in the clinical course of patients with pancreatic cancer and its significant association with prognosis. J Surg Oncol. 1999; 71(3):140-6. DOI: 10.1002/(sici)1096-9098(199907)71:3<140::aid-jso2>3.0.co;2-t. View